Tissue factor (TF) is an attractive target for cancer therapy due to its overexpression in multiple types of malignancies. In addition, TF has been reported to play functional roles in both cancer development and metastasis. Several groups have already developed antibody-drug conju- gates (ADCs) against TF for use as cancer treatments, and have demonstrated their efficacies in conventional subcu- taneous xenograft models and patient-derived xenograft models. However, no previous studies have investigated the effectiveness of anti-TF ADC in an advanced-stage cancer model. The present study developed an original humanized anti-TF monoclonal antibody conjugated with monomethyl auristatin E, and evaluated its in vivo efficacy in a pancre- atic cancer xenograft model with peritoneal dissemination. In vitro assays demonstrated that the anti-TF ADC had potent binding affinity and cytotoxic activity against human pancreatic cancer cells that strongly expressed TF antigens. The anti-TF ADC also exhibited greater antitumor effect than that of a control ADC in conventional subcutaneous xenograft models, with efficacy depending on the TF expres- sion in the tumor tissues. Furthermore, the anti-TF ADC significantly inhibited tumor growth in an orthotopic xeno- graft model, and extended the survival period in a murine peritoneal dissemination model. These results indicated that anti-TF ADC has the potential to be an effective treatment not only for primary tumors, but also for those that are widely disseminated. Therefore, it can be concluded that ADC targeting TF may be a promising agent for advanced pancreatic cancer therapy.
ASJC Scopus subject areas